{"filings":[{"id":184103,"accession_number":"0001683168-25-000009","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.","Original deal: $15M stock issuance at closing plus up to $15M milestone shares.","Extension allows more time for due diligence and drafting definitive agreements; no guarantee a deal will close.","Parties continue negotiating; prior expiration was December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216711,"accession_number":"0001683168-24-005057","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carlton Johnson resigns from Mosaic ImmunoEngineering board, effective July 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlton Johnson notified the Board of his resignation effective immediately on July 23, 2024.","He also resigned from all Board committees, including Audit and Compensation Committees.","Resignation is not due to any disagreement with the company regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236390,"accession_number":"0001683168-24-003923","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering CFO Paul Lytle moves to part-time, pay cut to $1,600/month","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Paul Lytle reduced to part-time effective June 1, 2024, max 8 hours/month, monthly rate $1,600.","All deferred unpaid compensation to be paid upon completion of a capital raise of at least $4M.","Company will grant RSUs equal to 20% of deferred salary on closing date of the capital raise.","Lytle no longer eligible for PTO or group insurance benefits under the revised arrangement.","Agreement reflects cost-containment efforts amid need for new funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236389,"accession_number":"0001683168-24-003732","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering changes auditor; KMJ resigns, Rose Snyder & Jacobs appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KMJ Corbin & Company resigned on May 21, 2024, after its partners joined Crowe LLP.","No adverse opinions or disagreements in fiscal years 2022 and 2023; going concern paragraph noted.","New auditor Rose, Snyder & Jacobs LLP engaged on May 22, 2024.","No reportable events or consultations with the new auditor prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236388,"accession_number":"0001683168-24-002761","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.","Initial $15M in common or preferred stock; milestone payments up to $15M more in shares.","Oncotelic to provide operational loan through June 1 and assist in raising $2M initial funding.","If funding fails, transaction may convert to reverse acquisition/merger; shareholder approval required.","Mosaic gains regulatory packages and access to Oncotelic's AI for immunotherapy combination discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236387,"accession_number":"0001683168-24-002534","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mosaic ImmunoEngineering announces passing of director Gloria Felcyn","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Gloria Felcyn died on April 17, 2024.","She had served as an independent director on the Board since 2002.","Felcyn was a member of the Audit, Compensation, and Corporate Governance and Nominating Committees.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254047,"accession_number":"0001683168-24-001813","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.","Amount owed to CWRU increased to approximately $407,000 as of Dec. 31, 2023; company lacks capital to pay.","Company evaluating strategic options including additional capital, M&A, or possible wind-down/liquidation.","License was for foundational technology (CPMV) behind MIE-101, the sole immunotherapy candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}